🚀 VC round data is live in beta, check it out!
InnovAge Valuation Multiples
Discover revenue and EBITDA valuation multiples for InnovAge and similar public comparables like Summerset Group Holdings, Ambea, Ryman Healthcare, Regis Healthcare and more.
InnovAge Overview
About InnovAge
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.
Founded
2015
HQ
Employees
2.4K
Website
Sectors
Financials (LTM)
EV
$1B
InnovAge Financials
InnovAge reported last 12-month revenue of $926M and EBITDA of $65M.
In the same LTM period, InnovAge generated $411M in gross profit, $65M in EBITDA, and $21M in net income.
Revenue (LTM)
InnovAge P&L
In the most recent fiscal year, InnovAge reported revenue of $854M and EBITDA of $34M.
InnovAge expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $926M | XXX | $854M | XXX | XXX | XXX |
| Gross Profit | $411M | XXX | $154M | XXX | XXX | XXX |
| Gross Margin | 44% | XXX | 18% | XXX | XXX | XXX |
| EBITDA | $65M | XXX | $34M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 4% | XXX | XXX | XXX |
| EBIT Margin | 3% | XXX | (2%) | XXX | XXX | XXX |
| Net Profit | $21M | XXX | ($30M) | XXX | XXX | XXX |
| Net Margin | 2% | XXX | (4%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
InnovAge Stock Performance
InnovAge has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
InnovAge's stock price is $8.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -1.6% | XXX | XXX | XXX | $-0.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInnovAge Valuation Multiples
InnovAge trades at 1.2x EV/Revenue multiple, and 16.8x EV/EBITDA.
EV / Revenue (LTM)
InnovAge Financial Valuation Multiples
As of April 18, 2026, InnovAge has market cap of $1B and EV of $1B.
Equity research analysts estimate InnovAge's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
InnovAge has a P/E ratio of 52.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 16.8x | XXX | 31.5x | XXX | XXX | XXX |
| EV/EBIT | 36.0x | XXX | (67.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | 7.1x | XXX | XXX | XXX |
| P/E | 52.2x | XXX | (36.8x) | XXX | XXX | XXX |
| EV/FCF | 20.1x | XXX | 37.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified InnovAge Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
InnovAge Margins & Growth Rates
InnovAge's revenue in the last 12 month grew by 9%.
InnovAge's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
InnovAge's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
InnovAge's rule of X is 32% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
InnovAge Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | 110% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 20% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
InnovAge Public Comps
See public comps and valuation multiples for other Long-Term Care comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| InnovAge | XXX | XXX | XXX | XXX | XXX | XXX |
| Summerset Group Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Ambea | XXX | XXX | XXX | XXX | XXX | XXX |
| Ryman Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Regis Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Healthcare Services Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
InnovAge M&A Activity
InnovAge acquired XXX companies to date.
Last acquisition by InnovAge was on XXXXXXXX, XXXXX. InnovAge acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by InnovAge
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialInnovAge Investment Activity
InnovAge invested in XXX companies to date.
InnovAge made its latest investment on XXXXXXXX, XXXXX. InnovAge invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by InnovAge
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout InnovAge
| When was InnovAge founded? | InnovAge was founded in 2015. |
| Where is InnovAge headquartered? | InnovAge is headquartered in United States. |
| How many employees does InnovAge have? | As of today, InnovAge has over 2K employees. |
| Who is the CEO of InnovAge? | InnovAge's CEO is Patrick Blair. |
| Is InnovAge publicly listed? | Yes, InnovAge is a public company listed on Nasdaq. |
| What is the stock symbol of InnovAge? | InnovAge trades under INNV ticker. |
| When did InnovAge go public? | InnovAge went public in 2021. |
| Who are competitors of InnovAge? | InnovAge main competitors are Summerset Group Holdings, Ambea, Ryman Healthcare, Regis Healthcare. |
| What is the current market cap of InnovAge? | InnovAge's current market cap is $1B. |
| What is the current revenue of InnovAge? | InnovAge's last 12 months revenue is $926M. |
| What is the current revenue growth of InnovAge? | InnovAge revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of InnovAge? | Current revenue multiple of InnovAge is 1.2x. |
| Is InnovAge profitable? | Yes, InnovAge is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of InnovAge? | InnovAge's last 12 months EBITDA is $65M. |
| What is InnovAge's EBITDA margin? | InnovAge's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of InnovAge? | Current EBITDA multiple of InnovAge is 16.8x. |
| What is the current FCF of InnovAge? | InnovAge's last 12 months FCF is $54M. |
| What is InnovAge's FCF margin? | InnovAge's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of InnovAge? | Current FCF multiple of InnovAge is 20.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.